Thymosin Alpha-1: Immune Modulation and Its Role in Chronic Illness

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide derived from the thymus gland that modulates both innate and adaptive immunity. FDA-approved in 37 countries for hepatitis B and C. Used off-label for immune deficiency, chronic infections, and cancer adjunct therapy. Dose: 1.6 mg SubQ twice weekly.

The Thymus and Immune Regulation

The thymus gland is the master regulator of the adaptive immune system, responsible for the maturation and education of T lymphocytes. With age, the thymus undergoes progressive involution, contributing to the immunosenescence that makes older individuals more vulnerable to infections, cancer, and autoimmune conditions. Thymosin Alpha-1 is one of the key peptides produced by the thymus that mediates its immune-regulatory functions.

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5, a preparation derived from calf thymus tissue. The synthetic version, marketed as Zadaxin (thymalfasin), is approved in 37 countries for the treatment of chronic hepatitis B and C, and as an adjunct to chemotherapy and vaccines in immunocompromised patients.

Mechanisms of Immune Modulation

Tα1 exerts its immunomodulatory effects through multiple pathways. It promotes the maturation and differentiation of T helper cells (particularly Th1 cells), enhances natural killer (NK) cell activity, stimulates dendritic cell function, and upregulates toll-like receptor expression on immune cells. Critically, Tα1 is an immune modulator rather than a simple immune stimulant — it can enhance immunity when it is deficient and suppress it when it is overactive.

Clinical Applications

Tα1 has been studied in viral hepatitis (approved in multiple countries), cancer (as an adjunct to chemotherapy), sepsis (clinical trials demonstrated reduced mortality), COVID-19 (multiple studies showed reduced mortality and ICU admission rates), and chronic fatigue and immune deficiency conditions. The standard clinical dose is 1.6 mg administered subcutaneously twice weekly.

Safety Profile

Tα1 has an excellent safety profile, with decades of clinical use across multiple countries. The most common adverse effects are mild injection site reactions. No serious adverse events have been consistently attributed to Tα1 in clinical trials.